Comparing available JAK inhibitors for treating patients with psoriasis.
Parker J FunkPatrick O PercheRohan SinghKatherine A KellySteven Richard FeldmanPublished in: Expert review of clinical immunology (2022)
Current treatments for psoriasis include topicals, phototherapy, and systemic therapy. The subcutaneous or intravenous route of biologic administration presents a challenge as patients often prefer oral medications over injections and because of anti-drug antibody development. Tofacitinib is effective and has an overall mild-to-moderate safety profile but includes an FDA black box warning for increased risk of cardiovascular events and malignancy. Other JAK inhibitors have an acceptable safety profile and are effective in early clinical trials. Poor topical medication adherence should be considered when evaluating JAK inhibitors. Oral JAK inhibitors may provide a preferable route of administration and improved clinical outcomes.
Keyphrases
- cardiovascular events
- clinical trial
- rheumatoid arthritis
- end stage renal disease
- coronary artery disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- cardiovascular disease
- emergency department
- transcription factor
- high dose
- randomized controlled trial
- prognostic factors
- type diabetes
- stem cells
- low dose
- mesenchymal stem cells
- wound healing
- bone marrow
- platelet rich plasma